^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Polivy (polatuzumab vedotin-piiq) (Microtubule inhibitor, CD79b-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Roche Press Release
    Title:

    Roche’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma

    Published date:
    05/25/2022
    Excerpt:
    Basel...announced that the European Commission (EC) has granted approval of Polivy® (polatuzumab vedotin) in combination with MabThera®(rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
    Secondary therapy:
    R-CHP
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Diffuse Large B-cell Lymphoma...Preferred Regimen...Polatuzumab vedotin+/-Rituximab
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Diffuse Large B Cell Lymphoma: Preferred regimens...Polatuzumab vedotin ± bendamustine ± rituximab
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Roche Press Release
    Title:

    Health Canada Authorizes POLIVY® (polatuzumab vedotin for injection) for the First-Line Treatment of Adults With Large B-Cell Lymphoma

    Published date:
    11/24/2022
    Excerpt:
    Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on November 14, 2022, Health Canada has authorized POLIVY® (polatuzumab vedotin for injection) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL
    Secondary therapy:
    R-CHP
    Trial ID:
    POLARIX
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Roche Press Release
    Title:

    CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma

    Published date:
    03/25/2022
    Excerpt:
    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Polivy® (polatuzumab vedotin) in combination with MabThera® (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL)....The CHMP opinion was based on efficacy and safety data from the phase III POLARIX study (GO39942)...
    Secondary therapy:
    R-CHP